Monitor whether the company can raise sufficient capital to fund operations through FDA approval of its Pivot product. Watch for Nasdaq compliance by June 29, 2026 deadline. Evaluate dilution impact from the large number of outstanding warrants (22.8 million shares) and options (7.4 million shares) that could significantly increase share count. Assess progress on commercialization timeline for the Pivot product.
Executive Summary
Modular Medical, Inc. (MODD) is conducting a best-efforts IPO to raise up to $12 million through the sale of common stock and warrants. The company is a pre-revenue medical device startup focused on developing a modern insulin patch pump (Pivot) for diabetes management. Despite FDA clearance for its initial product (MODD1), the company has not yet commercialized any products and faces substantial doubt about its ability to continue as a going concern due to significant operating losses and cash burn. The offering proceeds will be used to repay a short-term credit facility, fund FDA approval for the Pivot product, and support initial commercialization efforts.
Key Financial Metrics
Key Facts
- Pre-revenue medical device company with no commercialized products despite FDA clearance for MODD1
- Incurred net losses of $21.9 million for nine months ended December 31, 2025 and $18.8 million for year ended March 31, 2025
- Has $2.9 million in cash as of December 31, 2025 but needs additional funding to continue operations
- Received Nasdaq delisting warning for failing to maintain $1 minimum bid price and has until June 29, 2026 to regain compliance
- Recent history of dilutive financings including multiple warrant offerings and a reverse stock split authorization
- Intends to use IPO proceeds to repay $200,000 drawn from a $350,000 revolving credit facility from CEO James Besser
Financial Impact
No revenue, $21.9 million net loss for nine months ended December 31, 2025, $2.9 million cash on hand
Risk Factors
- Going concern risk due to insufficient cash to fund operations
- Dependence on successful FDA approval and commercialization of Pivot product
- Risk of Nasdaq delisting if minimum bid price not maintained
- Significant shareholder dilution from recent financings and outstanding warrants
- Intense competition from established medical device companies like Medtronic and Tandem Diabetes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001213900-26-021221 |
| Document: ea027813801ex10-13_modular.htm | 0001213900-26-021221 |
| Document: ea027813801ex1-1_modular.htm | 0001213900-26-021221 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | DEF 14A | $2.08 | awaiting T+60 | — | $1.65 (+20.67%) |
Aug 19, 2026 9w ago | EFFECT | $3.32 | awaiting T+60 | — | $1.65 (+50.30%) |
Aug 5, 2026 11w ago | S-3 | $2.03 | awaiting T+60 | — | $1.65 (+18.72%) |
Apr 23, 2026 26w ago | S-3 | $4.65 $2.64 | ▲ +43.16% | ▲ +48.18% | $1.65 (+64.48%) |
Apr 21, 2026 27w ago | 8-K | $5.00 $3.24 | ▲ +35.20% | ▲ +42.10% | $1.65 (+67.00%) |
Apr 21, 2026 27w ago | 424B5 | $5.00 $3.24 | ▲ +35.20% | ▲ +42.10% | $1.65 (+67.00%) |
Apr 16, 2026 27w ago | 8-K | $4.82 $3.99 | ▼ −17.22% | ▼ −24.27% | $1.65 (−65.77%) |
Mar 4, 2026 33w ago | 424B4 | $5.70 $5.14 | ▲ +9.82% | ▲ +19.91% | $1.65 (+71.05%) |
Mar 4, 2026 33w ago | EFFECT | $5.70 $5.14 | ▼ −9.82% | ▼ −19.91% | $1.65 (−71.05%) |
Feb 27, 2026 34w ago | S-1 | $7.41 $4.90 | ▲ +33.87% | ▲ +43.26% | $1.65 (+77.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers